DK0633931T3 - Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon - Google Patents

Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon

Info

Publication number
DK0633931T3
DK0633931T3 DK93907858T DK93907858T DK0633931T3 DK 0633931 T3 DK0633931 T3 DK 0633931T3 DK 93907858 T DK93907858 T DK 93907858T DK 93907858 T DK93907858 T DK 93907858T DK 0633931 T3 DK0633931 T3 DK 0633931T3
Authority
DK
Denmark
Prior art keywords
interferon
monoclonal antibodies
activity against
neutralizing activity
against type
Prior art date
Application number
DK93907858T
Other languages
English (en)
Inventor
Michael G Tovey
Patrick Benoit
Debborah Maguire
Ivan Plavec
Francois Meyer
Original Assignee
Medisup Internat N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medisup Internat N V filed Critical Medisup Internat N V
Application granted granted Critical
Publication of DK0633931T3 publication Critical patent/DK0633931T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93907858T 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon DK0633931T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400902A EP0563487A1 (en) 1992-03-31 1992-03-31 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
PCT/EP1993/000770 WO1993020187A1 (en) 1992-03-31 1993-03-30 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon

Publications (1)

Publication Number Publication Date
DK0633931T3 true DK0633931T3 (da) 2003-09-15

Family

ID=8211644

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02028948T DK1329459T3 (da) 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon
DK93907858T DK0633931T3 (da) 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02028948T DK1329459T3 (da) 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon

Country Status (18)

Country Link
US (5) US5919453A (da)
EP (3) EP0563487A1 (da)
JP (2) JP3836500B2 (da)
AT (2) ATE368055T1 (da)
AU (2) AU679909B2 (da)
BG (1) BG99141A (da)
CA (1) CA2133106C (da)
CZ (1) CZ236994A3 (da)
DE (2) DE69332997T2 (da)
DK (2) DK1329459T3 (da)
ES (2) ES2199941T3 (da)
FI (1) FI944509A (da)
HU (1) HUT69995A (da)
NO (1) NO943625L (da)
NZ (1) NZ251343A (da)
PT (2) PT633931E (da)
RU (1) RU94045826A (da)
WO (1) WO1993020187A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
CA2171955A1 (en) * 1993-09-17 1995-03-23 Michael G. Tovey Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
CN101612402A (zh) * 2001-01-09 2009-12-30 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
PL1631312T3 (pl) * 2003-04-23 2009-02-27 Squibb & Sons Llc Kompozycje i sposoby terapii choroby zapalenia jelit
KR100872210B1 (ko) * 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
WO2005059106A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Interferon alpha antibodies and their uses
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
PL2662390T3 (pl) 2004-06-21 2017-12-29 E. R. Squibb & Sons, L.L.C. Antyciała receptora interferonu alfa I oraz ich zastosowania
CN101056654A (zh) * 2004-10-07 2007-10-17 苏黎士大学 用于预防和治疗银屑病的i型干扰素阻断剂
AU2006213800B2 (en) 2005-02-10 2012-02-09 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US20070081995A1 (en) * 2005-06-22 2007-04-12 Genentech, Inc. Methods and compositions for targeting IFNAR2
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CA2713981C (en) 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2279207B1 (en) 2008-05-07 2015-09-09 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
SG183541A1 (en) * 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
WO2013134146A1 (en) * 2012-03-07 2013-09-12 The Regents Of The University Of California Methods and compositions for treating viral infections by blocking type i interferon activity
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US11136399B2 (en) 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
CN116333132A (zh) * 2019-01-31 2023-06-27 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953132A (en) 1955-10-27 1960-09-20 Baxter Laboratories Inc Parenteral solution equipment
US3066671A (en) 1959-10-27 1962-12-04 Milton J Cohen Disposable additive container
US3608550A (en) 1969-05-07 1971-09-28 Becton Dickinson Co Transfer needle assembly
BE791340A (fr) 1972-01-06 1973-03-01 Becton Dickinson Co Nouveaux procede et appareil de prelevement de culture et d'identification de micro-organismes des humeurs
US4024857A (en) 1974-12-23 1977-05-24 Becton, Dickinson And Company Micro blood collection device
US4300404A (en) 1977-12-01 1981-11-17 Becton, Dickinson And Company Liquid specimen container
US4116066A (en) 1977-12-12 1978-09-26 Becton, Dickinson And Company Specimen sampler cup
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2657881A1 (fr) * 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
IL99232A0 (en) * 1990-08-20 1992-07-15 Univ Columbia Methods for producing rna viruses from cdna
WO1992018626A1 (fr) * 1991-04-17 1992-10-29 Laboratoire Europeen De Biotechnologie POLYPEPTIDES HYDROSOLUBLES AYANT UNE HAUTE AFFINITE POUR LES INTERFERONS α ET $g(b)
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
ATE173630T1 (de) * 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
ES2186714T3 (es) * 1994-03-07 2003-05-16 Imperial College Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor

Also Published As

Publication number Publication date
NO943625D0 (no) 1994-09-29
NO943625L (no) 1994-11-11
RU94045826A (ru) 1996-11-10
HUT69995A (en) 1995-09-28
PT633931E (pt) 2003-09-30
HU9402823D0 (en) 1995-01-30
EP0563487A1 (en) 1993-10-06
BG99141A (bg) 1995-07-28
EP0633931B1 (en) 2003-05-21
US7465451B2 (en) 2008-12-16
WO1993020187A1 (en) 1993-10-14
DK1329459T3 (da) 2007-11-26
US20070128701A1 (en) 2007-06-07
US5919453A (en) 1999-07-06
US20080226647A1 (en) 2008-09-18
JP3836500B2 (ja) 2006-10-25
EP1329459B1 (en) 2007-07-25
PT1329459E (pt) 2007-11-07
ATE368055T1 (de) 2007-08-15
EP1329459A2 (en) 2003-07-23
CA2133106C (en) 2009-06-30
EP0633931A1 (en) 1995-01-18
NZ251343A (en) 1997-07-27
US6787634B2 (en) 2004-09-07
ES2290241T3 (es) 2008-02-16
DE69334158D1 (de) 2007-09-06
AU679909B2 (en) 1997-07-17
EP1329459A3 (en) 2003-09-10
US7179465B2 (en) 2007-02-20
US20040191840A1 (en) 2004-09-30
ATE241008T1 (de) 2003-06-15
CA2133106A1 (en) 1993-10-14
JPH07505526A (ja) 1995-06-22
US20020055492A1 (en) 2002-05-09
CZ236994A3 (en) 1995-02-15
DE69332997T2 (de) 2004-05-19
FI944509A0 (fi) 1994-09-29
AU3890793A (en) 1993-11-08
DE69332997D1 (de) 2003-06-26
DE69334158T2 (de) 2008-04-10
AU706473B2 (en) 1999-06-17
FI944509A (fi) 1994-11-29
AU2349697A (en) 1997-07-24
JP2006089494A (ja) 2006-04-06
ES2199941T3 (es) 2004-03-01

Similar Documents

Publication Publication Date Title
DK0633931T3 (da) Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon
DK0502812T3 (da) Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
DE68929384D1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ATE348157T1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
DE69634079D1 (de) Antagoniste des vasculären endothelzellewachstumfaktors
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
FI964845A (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
PT1011723E (pt) Factor de crescimento tumorigenico de 88 kda e antagonistas
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE69115917D1 (de) Humane gammainterferonantagonisten
DK1283217T3 (da) Antistoffer mod IL-8-receptoren og deres terapeutiske anvendelser
EP0948536A4 (en) PROTEIN G ASSOCIATED RECEPTOR HAVING ENLARGED EXTRACELLULAR DOMAIN
ATE208403T1 (de) Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie